Compare Box Inc (BOX) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Box Inc vs Crispr Therapeutics AG — how do they compare? Box Inc trades at $32.44 (market cap $4.55B), while Crispr Therapeutics AG trades at $53.7 (market cap $5.23B). The key difference: Box Inc and Crispr Therapeutics AG are close in size by market cap, and Box Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| BOX | CRSP | |
|---|---|---|
Market Cap | $4.55B | $5.23B |
Sector | Technology | Health |
52-Week High | $33.60 | $76.78 |
52-Week Low | $21.37 | $44.34 |
Enterprise Value | $5.10B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BOX trades at $33.6, up 1.08% today, with a bullish technical signal and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income reaching $244.62M and a high gross margin of 79.56%. Recent news highlights Box's AI-ready content platform adoption, such as the Quintas Energy partnership announced on July 30, 2026.
The outlook is positive with a $37 consensus price target, but risks include a high P/E of 51.3 and competitive pressures. Earnings beat expectations in two of the last three quarters, supporting growth momentum, though valuation remains elevated relative to peers.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
